Brevan Howard Capital Management LP Invests $92,000 in Health Catalyst, Inc. (NASDAQ:HCAT)

Brevan Howard Capital Management LP purchased a new position in Health Catalyst, Inc. (NASDAQ:HCAT) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 13,065 shares of the company’s stock, valued at approximately $92,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HCAT. Impax Asset Management Group plc raised its holdings in Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after acquiring an additional 195,525 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Health Catalyst by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 39,355 shares of the company’s stock worth $278,000 after purchasing an additional 8,451 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Health Catalyst in the fourth quarter valued at approximately $2,044,000. Intech Investment Management LLC increased its holdings in shares of Health Catalyst by 59.7% in the fourth quarter. Intech Investment Management LLC now owns 28,386 shares of the company’s stock valued at $201,000 after purchasing an additional 10,611 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in Health Catalyst during the fourth quarter worth approximately $110,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $4.52 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The firm has a market cap of $317.35 million, a P/E ratio of -3.35 and a beta of 1.56. The firm’s 50 day moving average price is $4.13 and its 200-day moving average price is $5.89. Health Catalyst, Inc. has a one year low of $3.56 and a one year high of $9.24.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of Health Catalyst stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now directly owns 160,437 shares of the company’s stock, valued at $729,988.35. The trade was a 7.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Linda Llewelyn sold 6,441 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total transaction of $34,974.63. Following the sale, the insider now owns 85,819 shares in the company, valued at $465,997.17. This trade represents a 6.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,588 shares of company stock valued at $217,259 over the last quarter. 2.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. KeyCorp dropped their target price on Health Catalyst from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, April 16th. Evercore ISI lowered shares of Health Catalyst from an “outperform” rating to an “inline” rating in a report on Wednesday, April 9th. Stephens reduced their target price on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Royal Bank of Canada decreased their target price on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Thursday, February 27th. Finally, Wells Fargo & Company cut their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.